Atripla | Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate Tablet Breastfeeding
For most of the drugs advantages of taking medications overweighs the potential risks however some drugs could be really dangerous for breastfed baby hence every medication shall be considered separately. In this page we will discuss about purpose of Atripla | Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate Tablet and its risk associated with lactation. We will also discuss the usage of Atripla | Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate Tablet and some common side effects associated with Atripla | Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate Tablet.

What is Atripla | Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate Tablet ?


ATRIPLA® is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.

Is using Atripla | Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate Tablet safe or dangerous while breastfeeding?

Atripla | Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate Tablet high risk while breastfeeding
As Atripla | Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate Tablet is made of only Efavirenz, and Efavirenz is unsafe to use in breastfeeding we can safely reach on conclusion that Atripla | Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate Tablet is also unsafe to use while breastfeeding. Below is detailed analysis of Efavirenz and Atripla | Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate Tablet during location. We recommend you to go through provided detailed analysis as below take decision accordingly. We also recommend you talk to your health care provider before making final decision.

Atripla | Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate Tablet Breastfeeding Analsys


Efavirenz while Breastfeeding

Unsafe

CAS Number: 154598-52-4

Anti-HIV drug. There is not experience on children younger than 3 years old. Mothers must be adviced that transmission of HIV infection through breastfeeding has been documented.


Atripla | Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate Tablet Breastfeeding Analsys - 2


Efavirenz while Breastfeeding

CAS Number: 154635-17-3

In the United States and other developed countries, HIV-infected mothers should generally not breastfeed their infants. Published experience with efavirenz during breastfeeding is limited. In countries in which no acceptable, feasible, sustainable and safe replacement feeding is available, World Health Organization guidelines recommend that all women with an HIV infection who are pregnant or breastfeeding should be maintained on antiretroviral therapy for at least the duration of risk for mother-to-child transmission. Mothers should exclusively breastfeed their infants for the first 6 months of life; breastfeeding with complementary feeding should continue through at least 12 months of life up to 24 months of life.[1] The first choice regimen for nursing mothers is tenofovir, efavirenz and either lamivudine or emtricitabine. If these drugs are unavailable, alternative regimens include: 1) zidovudine, lamivudine and efavirenz; 2) zidovudine, lamivudine and nevirapine; or 3) tenofovir, nevirapine and either lamivudine or emtricitabine. Exclusively breastfed infants should also receive 6 weeks of prophylaxis with nevirapine.[2][3] Treatment of mothers of HIV+ mothers with efavirenz as part of Option B+ therapy does not appear to affect growth of their HIV-negative breastfed infants.


Atripla | Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate Tablet and breastfeeding

What should I do if I am breastfeeding mother and I am already exposed to Atripla | Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate Tablet?

We have already established that Atripla | Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate Tablet is unsafe in breastfeeding and breastfeeding while using Atripla | Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate Tablet is not a good idea however if have already used and then breastfed the baby then you shall monitor the behavior and health of baby closely and inform your doctor as soon as possible. In case of emergency please call 911.


My doctor has prescribed me Atripla | Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate Tablet, what should I do?

If your doctor knows that you are breastfeeding mother and still prescribes Atripla | Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate Tablet then there must be good reason for that as Atripla | Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate Tablet is considered unsafe, It usually happens when doctor finds that overall advantage of taking outweighs the overall risk.


If I am using Atripla | Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate Tablet, will my baby need extra monitoring?

Yes, Extra monitoring is required if mother is using Atripla | Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate Tablet and breastfeeding as it is considered unsafe for baby.


Who can I talk to if I have questions about usage of Atripla | Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate Tablet in breastfeeding?

US
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday

UK
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700

Australia
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week

Canada
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week